Pymaceuticals Analysis/Write-Up

Jahin Fayyaz (Fez)

1. By looking at the ‘Tumor Response to Treatment’ graph/data, it is clear that tumor volume decreased with the drug Capomulin, compared to drugs Infubinol, Ketapril, and the placebo.
2. By looking at the ‘Metastatic Spread During Treatment’ graph/data, it is clear that metastatic site spread across time is lower with the drug Capomulin, compared to drugs Infubinol, Ketapril, and the placebo.
3. By looking at ‘Survival During Treatment’ graph/data, it is clear that those who were administered the drug ‘Capomulin’ have a higher chance at survival, than those who were administered the drugs Infubinol, Ketapril, and the placebo.
4. By looking at the ‘Tumor Change Over 45 Day Treatment’ graph/data, we can conclude that Capomulin is better treatment given that tumor volume decreased by 19% compared to the drugs Infubinol, Ketapril, and the placebo where tumor volume increased by at least 46%.
5. By looking at the tumor percent change data, out of the nine total drugs (not including the placebo), Ramicine is better drug treatment for tumors compared to Capomulin. In fact, it is the best possible drug to provide compared to everything.
6. Although looking at the three specified drugs and the placebo, provided some good insight, it would have been the most beneficial to compare and plot all nine drugs and the placebo to better evaluate treatment options.